Personalized Medicine

‘Sci-Fi Stuff’: Yosemite Investor Matt Bettonville On Emerging Oncology Tech

 
• By 

In an interview with Medtech Insight, Matt Bettonville, investor at cancer-focused venture firm Yosemite, discussed its criteria for evaluating potential investments in oncology and his outlook on the future oncology landscape.

EMA Proposes Guidance On Oligonucleotide Drugs Amid Growing Role In Personalized Medicine

 

The draft guidance addresses specific requirements for oligonucleotide-based medicines that are not answered in existing guidance documents, and has been two years in the making.

Why CAR T Therapies Are Hard To Scale, And How Challenges Can Be Solved

 

Chimeric antigen receptor T-cell (CAR-T) therapies have revolutionized the treatment of blood cancer, but scalability remains a major challenge. Experts explain how technologies such as chip-based miniaturized models and automation could be part of the solution.  

EMA Updates Pre-Authorization Procedural Advice To Cover Joint Clinical Assessments

 

Two new pieces of guidance, from the EMA and the HTA coordination group respectively, should help companies understand which drugs must undergo an EU-wide joint clinical assessment and how to notify the relevant authorities about them.

‘Is This Doomsday Concern, Or Is It Reality?’ Verily CMO On AI’s Future, Lightpath Metabolic, More

 
• By 

Andrew Trister, Verily’s chief medical and scientific officer, discusses Verily’s newly launched Lightpath Metabolic solution, featuring GLP-1 prescription, AI and strengthened clinical support. Plus, the Google health tech spinout's plans for the Study Watch, the Alzheimer’s research landscape, and AI development and regulation in a new era of uncertainty.

‘Is This Doomsday Concern, Or Is It Reality?’ Verily CMO On AI’s Future, Lightpath Metabolic, More

 
• By 

Andrew Trister, Verily’s chief medical and scientific officer, spoke with Medtech Insight at the HLTH Europe conference about Verily’s newly launched Lightpath Metabolic solution, featuring GLP-1 prescription, AI and strengthened clinical support. Trister also talked about plans for the Study Watch and offered views on the Alzheimer’s research landscape and AI development and regulation in a new era of uncertainty.

EU Substances Of Human Origin Regulation Set To Pass Final Milestones

 

New regulation on  substances of human origin (SoHO) will help improve Europe’s “strategic autonomy” and improve access to such substances, say industry representative.

Podcast: ‘Pharma Is Not Just A Cost Component’ – Showcasing Value As Well As Innovation

 

Astellas Pharma’s chief commercial officer discusses the biopharma industry’s responsibility to drive change in health care.    

Women’s Health Innovation: What Are We Waiting For?

An investigator, an investor and an inventor walk into the New York Stock Exchange, and it’s no joke. Women’s health is a fruitful investment with a clear path to financial return. 

England’s Genomics Service Working With Industry On Precision Medicine & Personalized Vaccines

 

England’s chief scientific officer explains how the NHS Genomic Medicine Service has led to faster access to targeted cancer drugs and outlines the organization’s ongoing work in pharmacogenomics, liquid biopsies and personalized RNA vaccines.

Twin Health Extends AI-Powered Program To Help Healthy People Sustain Weight Loss Without GLP-1

 
• By 

Twin Health extends its whole-body digital twin AI platform to help people who are overweight or obese achieve a healthy weight without the use of medications.

Podcast: Closed Loop Medicine – Pairing Software With Drugs To Optimize Dosing

 
• By 

In this episode of the In Vivo podcast, Hakim Yadi, CEO and co-founder of UK techbio Closed Loop Medicine, discusses how the company is pairing software and predictive analytics with medications old and new to tailor drug dosing.  

Telehealth Experts Discuss Access In Health Care Deserts, Overcoming Provider Resistance, Liability Concerns

 
• By 

Virtual care leaders at Providence and Sanford Health shared successes and challenges in implementing remote monitoring and telehealth programs during a panel discussion at the recent Reuters Digital Health conference in San Diego.

DeepPsy Launches EEG/ECG Analysis For Precision Mental Health Treatment

 
• By 

Swiss-based start-up DeepPsy aims to streamline mental health care using EEG and ECG biomarkers to better match depression patients with treatments. Co-founder Mateo de Bardeci discusses the company’s vision as it launches its in-house medical device as a service in Switzerland.

‘Mental Health, Beyond Medication’: Motif Targets Depression With Minimally Invasive DOT

 
• By 

Motif’s “pea-sized” Digitally programmable Over-brain Therapeutic (DOT) requires 20 minutes to implant and can be activated at home with a wearable to “lift the fog” for people with depression. Motif CEO Jacob Robinson believes data captured by brain-computer interfaces and continuous monitoring will eventually be able to identify key biomarkers that enable psychiatrists to head off mental health crises.

The UK’s Cancer Vaccine Partnership With BioNTech Is Another First – But Can It Deliver?

 

BioNTech and the UK government's alliance to bring personalized cancer immunotherapy to patients is making progress, but the National Health Service has to show it can deliver on clinical trials recruitment.

Senseonics Wins Marketing Authorization For Novel Insulin Delivery System

 

The US FDA has cleared a glucose monitoring system from Senseonics. The authorization of the implantable insulin delivery system creates a new pathway for like devices.

Alarming Rise Of Diabetes in Several US States, Study Shows

 

A study of diabetes rates across the US over four years reveals significant increases in the disease in many states. Tobias Oerum, diabetes advocate and cofounder of the company that conducted the study, discussed the data and some of the factors contributing to this troubling trend with Medtech Insight.

Estonian Biobank’s Personalized Medicine Project To Unlock New Insights For Drug R&D

 

A new center for personalized medicine in Estonia will see PacBio’s long-read whole genome sequencing technology used to unlock new information about how genetics impact patients’ drug responses, experts from the project tell the Pink Sheet.

Pharma On The Hunt For Oncology Partners Across Modalities

 
• By 

The Inaugural AACR Oncology Industry Partnering Event gave pharma firms an opportunity to tell potential cancer drug collaborators what they need from external sources.

ADVERTISEMENT